SISCAPA Assay Technologies

Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.

A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.

The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.

While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.

The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.

Having gained traction for its technology in the RUO and LDT spaces, the company is now looking to develop its reagents for use in regulatory-cleared IVDs.

NEW YORK (GenomeWeb) – Precision Antibody in partnership with SISCAPA Assay Technologies has completed a Phase I SBIR contract from the National Cancer Institute to develop antibodies for mass spec-based protein biomarker assays.

NEW YORK (GenomeWeb) – New England Peptide and SISCAPA Assay Technologies are collaborating to manufacture and sell stable isotope standard peptides for use in SISCAPA's protein quantification assays.

NEW YORK (GenomeWeb) – Agilent Technologies and SISCAPA Assay Technologies said today that they have signed a non-exclusive agreement to provide complete workflows for targeted protein quantitation.

NEW YORK (GenomeWeb) – SISCAPA Assay Technologies said this week that it has closed a Series A financing round.

Pages

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.